Fmr LLC purchased a new stake in Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 879,100 shares of the company’s stock, valued at approximately $3,648,000. Fmr LLC owned about 2.17% of Aerpio Pharmaceuticals at the end of the most recent quarter.
Shares of Aerpio Pharmaceuticals stock opened at $2.60 on Friday. Aerpio Pharmaceuticals Inc has a 52 week low of $2.52 and a 52 week high of $6.25.
Aerpio Pharmaceuticals (OTCMKTS:ARPO) last issued its quarterly earnings data on Tuesday, August 14th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.02. The company had revenue of $1.33 million during the quarter. On average, analysts anticipate that Aerpio Pharmaceuticals Inc will post -0.89 EPS for the current fiscal year.
Several brokerages recently commented on ARPO. HC Wainwright set a $9.00 target price on Aerpio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 15th. Zacks Investment Research upgraded Aerpio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research report on Monday, August 20th. Needham & Company LLC began coverage on Aerpio Pharmaceuticals in a research report on Monday, July 23rd. They set a “buy” rating and a $10.00 target price on the stock. Finally, Guggenheim began coverage on Aerpio Pharmaceuticals in a research report on Wednesday, September 19th. They set a “buy” rating and a $10.00 target price on the stock.
Aerpio Pharmaceuticals Profile
Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.
Featured Article: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.